Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain

Boehringer Ingelheim

Status: Completed

Conditions: Idiopathic Pulmonary Fibrosis

Treatments: Drug: L01X - Other antineoplastic agents; Drug: L01 - Antineoplastic agents; Drug: L - Antineoplastic and immunomodulating agents; Drug: L01XE - Protein kinase inhibitors; Drug: L01XE31 - Nintedanib

Study type: Observational

Funder types: Industry

Identifiers

NCT03281200

1199-0295

Details and patient eligibility

About

The present study has been designed to characterize IPF patients treated with nintedanib (OFEV®), at time of treatment initiation, with respect to their clinical profile based on real-world data from January 2016 in Spanish Pulmonology Services.

Enrollment: 172 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patient is at least 18 years old
• The patient has IPF diagnosis according to most recent ATS/ERS/JRS/ALAT IPF guideline for diagnosis and management [5]
• The patient newly initiated treatment with nintedanib (OFEV®) since 01 January 2016 up to end of data collection date, according to the approved local Summary of Product Characteristics (SmPC)

Exclusion criteria

• Patients treated with nintedanib within a clinical trial or named-patient program or with any prior treatment of nintedanib.

Trial design

172 participants in 5 patient groups

Anatomical main group:

Treatment:

Drug: L - Antineoplastic and immunomodulating agents

Therapeutic subgroup

Treatment:

Drug: L01 - Antineoplastic agents

Pharmacological subgroup

Treatment:

Drug: L01X - Other antineoplastic agents

Chemical subgroup

Treatment:

Drug: L01XE - Protein kinase inhibitors

Chemical substance

Treatment:

Drug: L01XE31 - Nintedanib